438 related articles for article (PubMed ID: 27393516)
1. Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases.
Dudnik E; Yust-Katz S; Nechushtan H; Goldstein DA; Zer A; Flex D; Siegal T; Peled N
Lung Cancer; 2016 Aug; 98():114-117. PubMed ID: 27393516
[TBL] [Abstract][Full Text] [Related]
2. Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient.
Gion M; Remon J; Caramella C; Soria JC; Besse B
Lung Cancer; 2017 Jun; 108():72-74. PubMed ID: 28625652
[TBL] [Abstract][Full Text] [Related]
3. A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia.
Fujimoto D; Morimoto T; Ito J; Sato Y; Ito M; Teraoka S; Otsuka K; Nagata K; Nakagawa A; Tomii K
Lung Cancer; 2017 Sep; 111():1-5. PubMed ID: 28838377
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer.
Crinò L; Bronte G; Bidoli P; Cravero P; Minenza E; Cortesi E; Garassino MC; Proto C; Cappuzzo F; Grossi F; Tonini G; Sarobba MG; Pinotti G; Numico G; Samaritani R; Ciuffreda L; Frassoldati A; Bregni M; Santo A; Piantedosi F; Illiano A; De Marinis F; Tamberi S; Giannarelli D; Delmonte A
Lung Cancer; 2019 Mar; 129():35-40. PubMed ID: 30797489
[TBL] [Abstract][Full Text] [Related]
5. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
[TBL] [Abstract][Full Text] [Related]
6. Intracranial complete response for non-small-cell lung cancer patient with negative PD-L1 expression of the lung using nivolumab.
Kitadai R; Zenke Y; Hishima T; Hosomi Y
Cancer Rep (Hoboken); 2022 Feb; 5(2):e1460. PubMed ID: 34042323
[TBL] [Abstract][Full Text] [Related]
7. Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases.
Gauvain C; Vauléon E; Chouaid C; Le Rhun E; Jabot L; Scherpereel A; Vinas F; Cortot AB; Monnet I
Lung Cancer; 2018 Feb; 116():62-66. PubMed ID: 29413052
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer.
De Braganca KC; Janjigian YY; Azzoli CG; Kris MG; Pietanza MC; Nolan CP; Omuro AM; Holodny AI; Lassman AB
J Neurooncol; 2010 Dec; 100(3):443-7. PubMed ID: 20440540
[TBL] [Abstract][Full Text] [Related]
9. Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series.
Kanazu M; Edahiro R; Krebe H; Nishida K; Ishijima M; Uenami T; Akazawa Y; Yano Y; Yamaguchi T; Mori M
Thorac Cancer; 2018 Dec; 9(12):1782-1787. PubMed ID: 30328672
[TBL] [Abstract][Full Text] [Related]
10. Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature.
Ruiz-Bañobre J; Pérez-Pampín E; García-González J; Gómez-Caamaño A; Barón-Duarte FJ; López-López R; Vázquez-Rivera F
Lung Cancer; 2017 Jun; 108():217-221. PubMed ID: 28625638
[TBL] [Abstract][Full Text] [Related]
11. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
12. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
[TBL] [Abstract][Full Text] [Related]
13. Long-lasting shrinkage in tumor mass after discontinuation of nivolumab treatment.
Kimura H; Sone T; Murata A; Koba H; Tambo Y; Hara J; Abo M; Kasahara K
Lung Cancer; 2017 Jun; 108():7-8. PubMed ID: 28625651
[TBL] [Abstract][Full Text] [Related]
14. The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer.
Tanvetyanon T; Creelan BC; Antonia SJ
Expert Rev Anticancer Ther; 2016 Sep; 16(9):903-10. PubMed ID: 27488231
[TBL] [Abstract][Full Text] [Related]
15. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
Rizvi NA; Mazières J; Planchard D; Stinchcombe TE; Dy GK; Antonia SJ; Horn L; Lena H; Minenza E; Mennecier B; Otterson GA; Campos LT; Gandara DR; Levy BP; Nair SG; Zalcman G; Wolf J; Souquet PJ; Baldini E; Cappuzzo F; Chouaid C; Dowlati A; Sanborn R; Lopez-Chavez A; Grohe C; Huber RM; Harbison CT; Baudelet C; Lestini BJ; Ramalingam SS
Lancet Oncol; 2015 Mar; 16(3):257-65. PubMed ID: 25704439
[TBL] [Abstract][Full Text] [Related]
16. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
Costa DB; Shaw AT; Ou SH; Solomon BJ; Riely GJ; Ahn MJ; Zhou C; Shreeve SM; Selaru P; Polli A; Schnell P; Wilner KD; Wiltshire R; Camidge DR; Crinò L
J Clin Oncol; 2015 Jun; 33(17):1881-8. PubMed ID: 25624436
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data.
Dudnik E; Moskovitz M; Daher S; Shamai S; Hanovich E; Grubstein A; Shochat T; Wollner M; Bar J; Merimsky O; Zer A; Goldstein DA; Hammerman A; Cyjon A; Shechtman Y; Abu-Amna M; Flex D; Roisman LC; Peled N;
Lung Cancer; 2018 Dec; 126():217-223. PubMed ID: 29254746
[TBL] [Abstract][Full Text] [Related]
18. Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer.
Grossi F; Genova C; Crinò L; Delmonte A; Turci D; Signorelli D; Passaro A; Soto Parra H; Catino A; Landi L; Gelsomino F; Tiseo M; Puppo G; Roila F; Ricciardi S; Tonini G; Cognetti F; Toschi L; Tassinari D; Scoppola A; Giannarelli D; Cortesi E
Eur J Cancer; 2019 Dec; 123():72-80. PubMed ID: 31671314
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic effect of nivolumab on non-small-cell lung cancer patients with brain metastases: a retrospective study].
Zhang GW; Cheng RR; Wang HJ; Zhang Y; Li P; Yan XT; Zhang MN; Zhang XJ; Yang JP; Ma ZY
Zhonghua Zhong Liu Za Zhi; 2020 Nov; 42(11):961-965. PubMed ID: 33256309
[No Abstract] [Full Text] [Related]
20. Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases.
Cortinovis D; Chiari R; Catino A; Grossi F; DE Marinis F; Sperandi F; Piantedosi F; Vitali M; Parra HJS; Migliorino MR; Tondini C; Tassinari D; Frassoldati A; Verderame F; Pazzola A; Cognetti F; Palmiotti G; Marchetti P; Santoro A; Giannarelli D; Colonese F; Delmonte A
Anticancer Res; 2019 Aug; 39(8):4265-4271. PubMed ID: 31366516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
